A sweeping review of Florida-centered medical records suggests that adults with obesity and autoimmune disease who used GLP-1 injection medications wound up with fewer dangerous venous blood clots and a sharply lower risk of dying from any cause. In this matched analysis, people on GLP-1 therapies had fewer venous thromboembolism events and a 44% drop in overall mortality, raising the possibility that these drugs may offer benefits that go beyond the bathroom scale, although researchers stress that more work is needed to confirm the signal.
The study team, working within the OneFlorida+ clinical research network, published its findings in the Journal of the American Heart Association after combing through electronic health records from 2014 to 2024. Using propensity-score matching, the investigators compared 13,204 adults taking GLP-1 receptor agonists with 13,204 similar adults who were not on the drugs, for a total of 26,408 people, according to the Journal of the American Heart Association.
Among the headline numbers, GLP-1 use was tied to a 17% lower risk of venous thromboembolism, a 31% lower risk of pulmonary embolism, and a 44% lower risk of death, according to the American Heart Association. "The 44% reduction in all-cause mortality observed among patients with obesity and co-occurring autoimmune disease is a striking finding," Fatima Cody Stanford said in the association's release. The researchers are clear that this kind of analysis cannot prove that the GLP-1 drugs directly caused the lower event rates.
How The Study Was Done And What It Cannot Prove
The team used a target-trial emulation approach in an effort to approximate a randomized trial within electronic health record data, matching patients on dozens of baseline characteristics. That design can trim back some types of bias but cannot get rid of unmeasured confounding altogether, and the authors explicitly note that factors such as weight loss or better glucose control could be mediators rather than direct drug effects, as detailed in the Journal of the American Heart Association. The analysis also grouped a wide range of autoimmune conditions, which limits how precisely the results apply to any single diagnosis.
What Might Be Driving The Clot Protection
Clinicians point out that GLP-1 receptor agonists typically lead to sustained weight loss, lower blood pressure, and improved lipid profiles, changes that could plausibly cut clotting risk by dialing down inflammation and improving endothelial function. Reviews of GLP-1 biology and cardiovascular outcomes have explored these mechanisms and suggest that any protective effect against clots may be mediated through anti-inflammatory and endothelial pathways, according to the Journal of Translational Medicine.
Why This Hits Close To Home In Florida
The OneFlorida+ clinical research network that powered the analysis pulls records from 14 health systems and more than 21 million adults across Florida and neighboring states, giving the findings an immediate local dimension. Lead author Amy Sheer is based at the University of Florida, and the results were presented at the American Diabetes Association meeting in early June, according to the American Heart Association.
What Doctors Are Saying And What Comes Next
Specialists emphasize that observational data like this should be treated as hypothesis-generating, not as a green light to change medications on your own. Current expert guidance suggests GLP-1 drugs do not appear to raise clot risk and that treatment decisions should be tailored to each patient, especially for people on blood thinners or with known clotting disorders, according to the University of Michigan.
